Pulmatrix Presents Preclinical Data on iSPERSE Inhaled Antibiotics at the 2014 Respiratory Drug Delivery Conference
Results Demonstrated the Enablement of High Drug Load Delivery with iSPERSE Dry Powder Delivery Technology
Lexington, MA, May 5, 2014 – Pulmatrix today presented data at the 2014 Respiratory Drug Delivery Conference in Fajardo, Puerto Rico. The poster presentation includes development data on PUR0400, a preclinical drug candidate of fluoroquinilone Levofloxacin formulated in the company’s proprietary iSPERSE™ dry powder technology.
Robert Clarke, PhD, Chief Executive Officer of Pulmatrix noted, “The development of PUR0400 marks a significant step for the company in advancing multiple iSPERSE programs towards clinical testing. These data significantly advance our understanding of our novel platform technology and highlight our ability to formulate high drug load products in a format that avoids liquid nebulization and is convenient to patients.”
The development data extend previous work performed with a wide range of antibiotic drug classes and focuses on PUR0400, an advanced dry powder formulation of Levofloxacin. The data demonstrate that, when formulated in iSPERSE, PUR0400 exhibits desirable physical and aerosol properties, while exhibiting stability across storage conditions.
David Hava, PhD, Chief Scientific Officer of Pulmatrix, commented, “The PUR0400 data highlight an advantage of the iSPERSE technology over conventional dry powder technologies in the stable formulation of high drug loads for lung delivery. Together with a robust preclinical data package using a number of different antibiotics, these data provide the support for continued development of inhaled antibiotic formulations in a number of respiratory diseases.”
PUR0400 was designed using Pulmatrix’s proprietary iSPERSE platform, an engineered particle technology that facilitates flow rate independent, high efficiency drug delivery to the lungs. PUR0400 is one of several iSPERSE antibiotic formulations being developed for respiratory diseases such as Cystic Fibrosis (CF) and non-CF bronchiectasis.
The Company is pursuing both proprietary and partnered applications for iSPERSE. For additional information about Pulmatrix, please visit www.pulmatrix.com.
iSPERSE™ is a trademark of Pulmatrix, Inc.
# # #